|
|
|
Insider
Information: |
Alles Mark J |
Relationship: |
Director |
City: |
Summit |
State: |
NJ |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
18,761 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$1,356,090 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
18,761 |
|
|
Total
Value |
$1,356,090 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
0
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
1
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-13.3%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
Syros Pharmaceuticals, Inc. |
SYRS |
Director |
2023-09-16 |
3,666 |
2020-05-13 |
0 |
Premium* |
|
Turning Point Therapeutics, Inc. |
TPTX |
Director |
2022-08-17 |
0 |
2021-06-21 |
0 |
Premium* |
|
Biomarin Pharmaceutical Inc |
BMRN |
Director |
2023-05-23 |
15,095 |
2022-01-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CELG |
Celgene Corp |
See Remarks |
|
2013-07-31 |
4 |
S |
$147.01 |
$14,172,646 |
D/D |
(96,406) |
4,946 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2015-02-06 |
4 |
AS |
$120.68 |
$14,131,156 |
D/D |
(117,099) |
56,902 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2013-07-31 |
4 |
OE |
$38.47 |
$5,332,913 |
D/D |
96,406 |
101,352 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2015-02-06 |
4 |
OE |
$25.77 |
$4,503,114 |
D/D |
107,859 |
174,001 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2015-02-06 |
4 |
D |
$118.75 |
$1,622,838 |
D/D |
(13,666) |
73,640 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2015-02-12 |
4 |
OE |
$25.77 |
$1,249,653 |
D/D |
27,505 |
101,145 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2016-02-12 |
4 |
D |
$102.45 |
$1,218,028 |
D/D |
(11,889) |
153,636 |
0 |
- |
|
CELG |
Celgene Corp |
CEO, CHAIRMAN OF BOARD |
|
2019-03-01 |
4 |
D |
$85.96 |
$1,194,844 |
D/D |
(13,900) |
212,278 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2014-02-12 |
4 |
D |
$160.54 |
$1,097,612 |
D/D |
(6,837) |
33,071 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2013-08-02 |
4 |
OE |
$62.35 |
$997,350 |
D/D |
15,000 |
19,946 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2017-02-14 |
4 |
D |
$117.02 |
$777,364 |
D/D |
(6,643) |
170,920 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2013-08-02 |
4 |
S |
$146.47 |
$732,335 |
D/D |
(5,000) |
14,946 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2013-11-01 |
4 |
D |
$151.31 |
$681,175 |
D/D |
(4,502) |
20,444 |
0 |
- |
|
CELG |
Celgene Corp |
CEO, CHAIRMAN OF BOARD |
|
2019-05-02 |
4 |
D |
$95.21 |
$630,290 |
D/D |
(6,620) |
221,266 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2016-01-29 |
4 |
OE |
$19.24 |
$603,586 |
D/D |
21,938 |
139,685 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2015-12-17 |
4 |
D |
$112.17 |
$602,353 |
D/D |
(5,370) |
117,747 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2013-12-27 |
4 |
D |
$168.93 |
$591,424 |
D/D |
(3,501) |
24,720 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2015-04-30 |
4 |
D |
$108.06 |
$556,941 |
D/D |
(5,154) |
111,447 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2016-04-29 |
4 |
D |
$103.41 |
$523,461 |
D/D |
(5,062) |
159,574 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2015-03-01 |
4 |
D |
$121.53 |
$495,599 |
D/D |
(4,078) |
105,401 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2016-12-02 |
4 |
D |
$117.63 |
$355,007 |
D/D |
(3,018) |
163,116 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Director |
|
2022-10-31 |
4 |
B |
$86.75 |
$314,469 |
D/D |
3,625 |
10,905 |
2.39 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2018-02-08 |
4 |
B |
$91.90 |
$299,594 |
D/D |
3,260 |
178,904 |
2.81 |
- |
|
CELG |
Celgene Corp |
CEO, CHAIRMAN OF BOARD |
|
2018-12-16 |
4 |
D |
$68.20 |
$264,343 |
D/D |
(3,876) |
192,369 |
0 |
- |
|
CELG |
Celgene Corp |
See Remarks |
|
2017-07-28 |
4 |
D |
$134.10 |
$259,081 |
D/D |
(1,932) |
173,188 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|